NCT05053035View on ClinicalTrials.gov

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

AL001

Administered via intravenous (IV) infusion

DRUG

Placebo

Administered via intravenous (IV) infusion

Trial Locations (3)

33612

University of South Florida, Tampa

63110

Washington University School of Medicine, St Louis

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Alector Inc.
All Listed Sponsors
lead

Alector Inc.

INDUSTRY